BeOne Medicines Ltd. (ONC) - Dilution Analysis

10-Q filing | 1442.5M shares outstanding

10-Q filing | 1432.8M shares outstanding

10-Q filing | 1408.2M shares outstanding

POS AM filing: This POS AM filing relates to a primary offering of securities, potentially including a preliminary prospectus, free writing prospectus, or other communications, and indicates that incorporated annual reports are considered new registration statements for the offered securities.

10-Q filing | 1390.1M shares outstanding

10-K filing | 1368.7M shares outstanding

10-Q filing | 1376.8M shares outstanding

10-Q filing | 1361.1M shares outstanding

10-Q filing | 1355.5M shares outstanding

10-K filing | 1357.0M shares outstanding

10-Q filing | 1360.7M shares outstanding

10-Q filing | 1360.2M shares outstanding

10-Q filing | 1354.2M shares outstanding

10-K filing | 1340.7M shares outstanding

8-K filing: BeiGene, Ltd. amended its Share Purchase Agreement with Amgen Inc., where Amgen relinquished its right to appoint a designated director to BeiGene's board due to BeiGene's global growth. ($2780.0M proceeds)

10-Q filing | 1345.3M shares outstanding

10-Q filing | 1336.5M shares outstanding

10-Q filing | 1332.0M shares outstanding

10-K filing | 1206.2M shares outstanding

8-K filing: BeiGene, Ltd. commenced an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange, offering 115,055,260 ordinary shares (or 132,313,260 shares if an over-allotment option is exercised in full).

8-K filing: BeiGene entered into an agreement for a STAR Offering of 115,055,260 ordinary shares (or 132,313,260 ordinary shares if an option is exercised) at RMB192.60 per share, with gross proceeds expected to be approximately US$3.5 billion. ($3500.0M proceeds)

10-Q filing | 1206.0M shares outstanding

10-Q filing | 1194.1M shares outstanding

10-Q filing | 1188.9M shares outstanding

10-K filing | 1190.8M shares outstanding

8-K filing: BeiGene announced a proposed STAR Offering of RMB shares, not exceeding 132,313,549 ordinary shares, representing no more than 10% of the sum of the total number of issued ordinary shares as of January 7, 2021 and the total number of the RMB Shares to be issued, to be listed on the STAR Market. ($3100.0M proceeds)

8-K filing: BeiGene, Ltd. entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, as the representative of the underwriters, related to a public offering of 1,511,546 American Depositary Shares (ADSs) of the Company by the Selling Shareholders at a price to the public of $225.00 per ADS.

10-Q filing | 1182.9M shares outstanding

8-K filing: BeiGene, Ltd. issued 206,635,013 ordinary shares in the form of 15,895,001 American Depositary Shares to Amgen Inc. for aggregate gross proceeds of approximately $2.78 billion on January 2, 2020. ($2780.0M proceeds)

10-Q filing | 1176.4M shares outstanding

8-K filing: BeiGene, Ltd. entered into a share purchase agreement to sell and issue 145,838,979 ordinary shares at $14.2308 per share, for gross proceeds of approximately $2.08 billion. ($2080.0M proceeds)

8-K filing: BeiGene, Ltd. announced its financial results for the three months ended March 31, 2020, and provided an update on business highlights and expected milestones for the remainder of 2020. The company also postponed the extraordinary general meeting of shareholders.

10-Q filing | 801.3M shares outstanding

8-K filing: BeiGene, Ltd. issued 206,635,013 ordinary shares to Amgen Inc. for approximately $2.78 billion, and Amgen has an option to purchase up to 75,000,000 additional ordinary shares to maintain its ownership at approximately 20.6% of the Company's outstanding share capital. ($2780.0M proceeds)

10-K filing | 776.3M shares outstanding

8-K filing: BeiGene, Ltd. closed the sale of 206,635,013 ordinary shares in the form of 15,895,001 American Depositary Shares to Amgen for an aggregate cash price of US$2.78 billion, or US$13.45 per ordinary share, or US$174.85 per ADS. ($2780.0M proceeds)